Alnylam Pharmaceuticals | ALNY - Stock

Stock Price
455.03
Daily Change
3.03 0.67%
Monthly
4.60%
Yearly
79.74%
Q3 Forecast
448.25

Alnylam Pharmaceuticals reported $71.69M in Stock for its fiscal quarter ending in June of 2025.



Financials
Stock Price USD
Assets USD 4.57B
Cash and Equivalent USD 1.11B
Cost of Sales USD 142.95M
Current Assets USD 3.64B
Current Liabilities USD 1.3B
Debt USD 1.3B
EBIT USD 4.89M
EBITDA USD 18.83M
Employees 2.23K
EPS Earnings Per Share USD 0.32
Equity Capital and Reserves USD 250.59M
Gross Profit on Sales USD 630.74M
Interest Expense on Debt USD 40.25M
Interest Income USD 27.49M
Loan Capital USD 1.03B
Market Capitalization USD 59.08B
Net Income USD -66.28M
Operating Expenses USD 789.89M
Operating Profit USD -16.2M
Ordinary Share Capital USD 130.98M
Pre-Tax Profit USD -35.36M
Sales Revenues USD 773.69M
Selling and Administration Expenses USD 323.31M
Stock USD 71.69M
Trade Creditors USD 102.39M
Trade Debtors USD 567.11M

Stock Change Date
Acadia Pharmaceuticals USD 26.12M 3.18M Jun/2025
Agios Pharmaceuticals USD 30.85M 1.24M Jun/2025
Alnylam Pharmaceuticals USD 71.69M 6.11M Jun/2025
Amgen USD 6.58B 146M Jun/2025
Arrowhead Research USD -173085000 173.08M Dec/2024
BioMarin Pharmaceutical USD 1.34B 65.32M Jun/2025
Incyte USD 83.42M 19.45M Jun/2025
Ionis Pharmaceuticals USD 8.48M 3.02M Jun/2025
Moderna USD 240M 112M Jun/2025
Neurocrine Biosciences USD 56.9M 2.2M Jun/2025
Novartis USD 6.31B 584M Jun/2025
PTC Therapeutics USD 34.06M 12.39M Jun/2025
Regeneron Pharmaceuticals USD 3.21B 760.7M Jun/2025
Sanofi EUR 9.62B 187M Jun/2025
Sarepta Therapeutics USD 994.04M 52.6M Jun/2025
Takeda JPY 1.24T 23.33B Jun/2025
Tectonic Therapeutic USD 0 0 Jun/2020
Ultragenyx Pharmaceutical USD 46.5M 467K Jun/2025
Vertex Pharmaceuticals USD 1.5B 139.6M Jun/2025
Xencor USD 0 0 Jun/2020